Phase I, Single-Blind, Placebo-Controlled Study of ABO21009 in Healthy Volunteers and Rheumatoid Arthritis Patients

The primary objective of this study is to evaluate the safety and tolerability of **ABO21009** in both healthy volunteers and patients diagnosed with **Rheumatoid Arthritis**. This is clinically relevant as it aims to determine the potential adverse effects and overall safety profile of the investigational product, which is crucial for assessing its suitability for further clinical development. The study is designed as a placebo-controlled, single-blind, phase I trial, providing initial insights into the drug's safety in a controlled environment.

The clinical trial focuses on individuals diagnosed with **Rheumatoid Arthritis**. The study population includes both male and female participants, encompassing a broad age range from young adults to older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants involved in the study. Participants were selected without any specific emphasis on lifestyle considerations such as diet, physical activity, or habits. The trial does not specify any key inclusion or exclusion criteria, as this information was not disclosed by the sponsor.

The clinical trial is a **placebo-controlled**, single-blind, phase I study designed to evaluate the safety and efficacy of ABO21009 in healthy volunteers and patients diagnosed with **Rheumatoid Arthritis**. The trial is scheduled to commence recruitment on February 6, 2025, and is anticipated to conclude by September 30, 2027. The study employs a single-blind methodology, ensuring that participants are unaware of whether they are receiving the active treatment or a placebo, while the investigators are informed. This design helps to minimize bias and allows for a more accurate assessment of the treatment's effects.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. Following successful screening, participants will be enrolled in the study and will attend regular follow-up visits to monitor their health status, assess treatment effects, and ensure adherence to the study protocol. The sequence and frequency of these visits will be determined by the study protocol, ensuring comprehensive data collection and participant safety. The trial will culminate in an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the intervention.

The expected duration of participant involvement will vary depending on the specific requirements of the study protocol, but it will generally span the entire trial period. Participants may be subject to early termination from the study if they experience adverse events, fail to comply with the study protocol, or withdraw consent. The study is conducted in accordance with ethical guidelines and regulatory requirements, ensuring the safety and well-being of all participants throughout the trial duration.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this clinical trial, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. The absence of these details suggests that the trial may focus solely on the experimental medication without a comparator or placebo group.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is February 6, 2025, with an anticipated end date of September 30, 2027. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, Phase 1 trials typically involve initial assessments of therapeutic effects alongside safety evaluations. The trial will likely employ standard methodologies appropriate for early-phase studies, potentially including laboratory tests and patient-reported outcomes, to gather preliminary data on efficacy. The absence of detailed endpoints suggests a focus on exploratory outcomes, which will be analyzed to inform subsequent trial phases.